» Articles » PMID: 12006425

Dyspnea is a Better Predictor of 5-year Survival Than Airway Obstruction in Patients with COPD

Overview
Journal Chest
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2002 May 15
PMID 12006425
Citations 294
Authors
Affiliations
Soon will be listed here.
Abstract

Background: FEV(1) is regarded as the most significant correlate of survival in COPD and is used as a measure of disease severity in the staging of COPD. Recently, however, the categorization of patients with COPD on the basis of the level of dyspnea has similarly been reported to be useful in the prediction of health-related quality of life and improvement in exercise performance after pulmonary rehabilitation.

Study Objectives: We compared the effects of the level of dyspnea and disease severity, as evaluated by airway obstruction, on the 5-year survival rate of patients with COPD.

Design And Methods: A total of 227 patients with COPD were enrolled in a 5-year, prospective, multicenter study in the Kansai area of Japan, involving 20 divisions of respiratory medicine from various university and city hospitals.

Results: After 5 years, 183 patients were available for the follow-up examination (follow-up rate, 81%). The 5-year cumulative survival rate among patients with COPD was 73%. The effect of disease staging, based on the American Thoracic Society (ATS) guideline as evaluated by the percentage of predicted FEV(1), on the 5-year survival rate was not significant (p = 0.08). However, the level of dyspnea was significantly correlated to the 5-year survival rate (p < 0.001). The Cox proportional hazards model revealed that the level of dyspnea had a more significant effect on survival than disease severity based on FEV(1).

Conclusions: The categorization of patients with COPD on the basis of the level of dyspnea was more discriminating than staging of disease severity using the ATS guideline with respect to 5-year survival. Dyspnea should be included as one of the variables, in addition to airway obstruction, for evaluating patients with COPD in terms of mortality.

Citing Articles

Dyspnea Management in Patients Presenting to the Emergency Department at Cantonal Hospital Baselland-A Retrospective Observational Study and Medical Audit.

Debernardi E, Jaun F, Boesing M, Leuppi J, Luthi-Corridori G J Clin Med. 2025; 14(4).

PMID: 40004907 PMC: 11856902. DOI: 10.3390/jcm14041378.


Differences in uni-dimensional breathlessness measures and thresholds for clinical response in a randomised controlled trial in people with chronic breathlessness: an exploratory study.

Ferreira D, Ekstrom M, Louw S, McCloud P, Johnson M, Clark K BMJ Open Respir Res. 2024; 11(1.

PMID: 39632100 PMC: 11624816. DOI: 10.1136/bmjresp-2024-002370.


Identifying Abnormal Exertional Breathlessness in COPD: Comparing Modified Medical Research Council and COPD Assessment Test With Cardiopulmonary Exercise Testing.

Ekstrom M, Lewthwaite H, Li P, Bourbeau J, Tan W, Jensen D Chest. 2024; 167(3):697-711.

PMID: 39490971 PMC: 11882773. DOI: 10.1016/j.chest.2024.10.027.


Translation and Linguistic Validation of the Multidimensional Dyspnea Profile into Hindi in a Palliative Care Setting.

Kokeritz M, Dufberg L, Palat G, Ekstrom M, Brun E, Segerlantz M Indian J Palliat Care. 2024; 30(3):252-259.

PMID: 39371501 PMC: 11450885. DOI: 10.25259/IJPC_46_2024.


The Effect of Opioids and Benzodiazepines on Exacerbation Rate and Overall Survival in Patients with Chronic Obstructive Pulmonary Disease on Long-Term Non-Invasive Ventilation.

Chai A, Csoma B, Lazar Z, Bentley A, Bikov A J Clin Med. 2024; 13(18).

PMID: 39337111 PMC: 11433445. DOI: 10.3390/jcm13185624.